Our expert for hiPSC-derived cardiac cells, as well as cell-based assays & services for drug safety and efficacy screenings
In order to translate an in vitro cardiac cellular model into the correct clinical interpretation of assay read-outs, a fully functional and validated model is needed.
This enables the assessment of safety pharmacology at the pre-clinical stage as well as drug efficacy testing. You can find our cardiomyocytes available as cryopreserved cells, or ready-to-go for specific applications in one of our CardioPlates™.
Fully functional hiPSC-derived cardiomyocytes for use in drug discovery and development. They are acquired through in vitro differentiation of transgenic hiPSCs and puromycin selection technology for the resulting pure population of cardiomyocytes.
hiPSC-derived cardiomyocytes with a fully functional, ventricular phenotype for use in drug discovery and development. They are acquired without genetic modifications, and cultured in a well-defined, serum-free culture medium that enhances their functionality and maturity.
hiPSC-derived primary-like ventricular cardiomyocytes, for research and drug development purposes. vCor.4U® Cardiomyocytes have a ventricular enriched phenotype and hold a 3-fold higher contraction profile compared to Cor.4U® Cardiomyocytes.
hiPSC-derived cardiac fibroblasts with characteristic electrochemical function and morphology essential for 2D and 3D co-culture assays with Cor.4U® or vCor.4U® Cardiomyocytes.
Pluricyte® Cardiomyocyte Differentiation Kit is a ready-to-use kit for generating high-quality contracting cardiomyocytes in adherent monolayer formats in a user friendly way. This kit is compatible with human pluripotent stem cells maintained in various media culture systems. Contracting cardiomyocytes can be generated within 14 days.